GC Cell Corporation

KOSDAQ:A144510 Stock Report

Market Cap: ₩353.9b

GC Cell Past Earnings Performance

Past criteria checks 0/6

GC Cell's earnings have been declining at an average annual rate of -6.5%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 22.6% per year.

Key information

-6.5%

Earnings growth rate

-7.0%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate22.6%
Return on equity-0.7%
Net Margin-1.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are Conservative

Mar 19
We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are Conservative

Recent updates

The Market Doesn't Like What It Sees From GC Cell Corporation's (KOSDAQ:144510) Revenues Yet As Shares Tumble 27%

Dec 01
The Market Doesn't Like What It Sees From GC Cell Corporation's (KOSDAQ:144510) Revenues Yet As Shares Tumble 27%

Revenues Working Against GC Cell Corporation's (KOSDAQ:144510) Share Price

Oct 14
Revenues Working Against GC Cell Corporation's (KOSDAQ:144510) Share Price

Is GC Cell (KOSDAQ:144510) A Risky Investment?

Sep 08
Is GC Cell (KOSDAQ:144510) A Risky Investment?

We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are Conservative

Mar 19
We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are Conservative

We Think Green Cross Lab Cell (KOSDAQ:144510) Can Stay On Top Of Its Debt

Feb 22
We Think Green Cross Lab Cell (KOSDAQ:144510) Can Stay On Top Of Its Debt

Can Green Cross Lab Cell Corporation (KOSDAQ:144510) Improve Its Returns?

Jan 18
Can Green Cross Lab Cell Corporation (KOSDAQ:144510) Improve Its Returns?

Can You Imagine How Jubilant Green Cross Lab Cell's (KOSDAQ:144510) Shareholders Feel About Its 139% Share Price Gain?

Dec 14
Can You Imagine How Jubilant Green Cross Lab Cell's (KOSDAQ:144510) Shareholders Feel About Its 139% Share Price Gain?

Revenue & Expenses Breakdown

How GC Cell makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A144510 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24184,356-3,38826,78123,796
30 Jun 24184,444-10,70825,84125,002
31 Mar 24186,623-6,80224,35325,045
31 Dec 23187,544-17423,13224,681
30 Sep 23182,085-10,81323,64127,611
30 Jun 23186,192-6,58922,57726,449
31 Mar 23194,327-94623,63527,279
31 Dec 22236,12026,53723,28426,426
30 Sep 22262,62151,81922,39323,260
30 Jun 22251,38252,69021,60121,514
31 Mar 22224,84850,93916,59819,388
31 Dec 21168,31031,42212,61818,490
30 Sep 21121,23115,4046,68117,282
30 Jun 21106,8108,7333,78616,564
31 Mar 2197,6199,5183,18714,795
31 Dec 2085,5624,1602,80813,961
30 Sep 2075,0832,2562,95412,672
30 Jun 2065,7625992,80813,698
31 Mar 2060,762-1,6702,64214,696
31 Dec 1957,895-2,2762,35415,110
30 Sep 1955,920-4211,93213,641
31 Dec 1850,6201,0022,2149,558

Quality Earnings: A144510 is currently unprofitable.

Growing Profit Margin: A144510 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A144510 is unprofitable, and losses have increased over the past 5 years at a rate of 6.5% per year.

Accelerating Growth: Unable to compare A144510's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A144510 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A144510 has a negative Return on Equity (-0.74%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 19:26
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GC Cell Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jinhee KwakEugene Investment & Securities Co Ltd.
Seung-Ho LeeNH Investment & Securities Co., Ltd.